Frequently Asked Questions
AI in healthcare
Vision, Mission and Goals

AI in healthcare in this context is defined as modern machine learning used to enable data-driven solutions to healthcare challenges. Modern machine learning incorporates techniques, such as Deep Learning, Random Forrest, and Gradient Boosting. It does not include classical techniques, such as linear regression. Healthcare is defined as anything relating to the diagnosis and treatment of a disease through chemical, biological or technical intervention. Healthcare does not include preventative solutions, such as, life style management.

Artificial Intelligence is the broader concept of machines being able to carry out tasks in a way that we would consider “smart”. Machine Learning is a subset of AI based around the concept of iterative learning in which a system ‘learns’ from data input and modifies activity without human intervention. Please note that in our definition of both Machine Learning and AI, AAIH includes iterative, feedback-based learning between machine and man.

Leading companies developing Healthcare AI platforms and products recognized that the rapid growth and momentum of the industry presents an ideal opportunity to convene and advocate for policies and a regulatory framework more conducive to commercial implementation of AI platforms. This group approached Adjuvant Partners and Holland & Knight due to their familiarity with the sector, and proven track record of launching successful stakeholder organizations in other healthcare technology sectors: The Alliance for Regenerative Medicine (ARM) and the Biotechnology Industry Organization (BIO).

AAIH is the global advocacy organization for the advancement and use of artificial intelligence in healthcare to improve patients’ lives and create more efficient, sustainable, and accessible healthcare systems. Through investment, invention, and innovation in AI, the AAIH and its member companies and organizations are creating novel interventions and product solutions that reduce failure rates and costs, and improve quality across the entire healthcare spectrum.

  • Distinguish between hype and reality, set achievable expectations
  • Engage in educational outreach to unify industry voice, define AI in public arenas
  • Advocate for informed policy and appropriate regulatory standards
  • Unify the industry around key priorities, identify bottlenecks, and develop strategic industry wide approaches for resolution

Artificial Intelligence can be deployed at every level of the healthcare system to improve healthcare efficiencies. AAIH members are using AI to disrupt all aspects of the healthcare management chain including in discovery, development, and delivery. AAIH members are utilizing:

  • Biomedical Discovery: Through use of AI platforms, the industry can reduce failure rates in biomedical discovery by increasing the capacity to test an increased number and quality of druggable targets. This will improve the efficacy and availability of compounds available for a widely expanded range of indications.
  • Point of Care Delivery: Using AI platforms for clinical data management permits early and accurate diagnosis of a range of medical conditions through improved data aggregation, analysis, and pattern recognition. As a result, complicated data sets can be rapidly interrogated to drive early and effective treatment interventions.

AAIH is a global advocacy organization for the advancement and use of artificial intelligence in healthcare.  AAIH’s advocacy work will entail working with regulators and policy makers, including senior officials from the US Food and Drug Administration (FDA), Members of the US Congress, representatives of the European Medical Association, and Members of European Parliament.  AAIH will educate policy makers about how artificial intelligence can be used in healthcare to improve patients’ lives and create more efficient, affordable, and accessible healthcare systems.

US law requires organizations that engage in sufficient “lobbying activities” (as defined in law) to publicly register as lobbyists under the federal Lobbying Disclosure Act (LDA) and under some analogous state laws.  As presently constituted, AAIH will not have employees, and therefore will not have to register under the LDA.  However, if necessary AAIH anticipates engaging third-party consultants who will make contact with at least two “covered officials” (including Members of Congress and/or senior FDA or other Executive Branch officials) and if they spend more than twenty-percent of their time for AAIH engaged in lobbying activity, these consultants will be required to register individually as lobbyists, and must name AAIH as a lobbying client.  In addition, pursuant to federal tax laws, if AAIH advocates for or against the passage of legislation, then it will advise its members of the percentage of their dues utilized to engage in such activity, which will not be tax deductible as a business expense.  AAIH has retained experienced legal counsel to advise on these matters.

The organization will establish a presence in Washington DC, the European Union, and other primary regulatory jurisdictions as the primary voice for the AI in healthcare industry. It will build a positive and constructive relationship with the regulatory authorities and build awareness and appreciation for the use of AI technology platforms in improving the quality, efficiency, and access to transformative therapies, better and more accurate diagnostics, and an affordable patient-centric healthcare system.

The organization will be successful in integrating AI platforms into the healthcare regulatory frameworks of multiple jurisdictions to stimulate innovation in drug discovery and to improve the overall quality of care. In addition, the AAIH will foster a more realistic understanding within investment and consumer populations on both the potential benefits and practical limitations of AI/ML in healthcare.

AAIHcontacticon
Organizational Structure, Type and Composition

Founding members currently include Amazon WS, BlackThorn Therapeutics, The Buck Institute for Research on Aging, Cyclica, Envisagenics, GE Healthcare, GlaxoSmithKline, Insilico Medicine, Novartis, NuMedii, Numerate, Nuritas, OWKIN, Recursion, and the University of Pittsburgh. We continue to seek members to diversify our foundational platforms and applications across the healthcare value chain.

  • Biomedical Discovery: AI enabled identification of new disease mechanisms, pathways, targets, drugs, diagnostics, and devices by various approaches including imaging and in-silico
  • Clinical Research: AI enabled acceleration and facilitation of Phase I-IV clinical trials including patient stratification, enrollment, retention, adherence, and monitoring as well as project management approaches.
  • Medical Diagnostics and Devices: AI approaches that enable image, drug/device, or treatment enhancement; may include diagnostics, wearables and implantables.
  • Precision Medicine: AI based approaches that enhance patient or population health solutions and care; includes patient data, and risk analytics, and genomics.

AAIH is a non-profit tax-exempt dues-based membership and advocacy organization, a 501c(4). Dues will be assessed based on a scale relating to size and revenues of a company or organization. A portion of dues will be tax deductible. We anticipate that the organization will be governed by a Board of 15-20 individuals who represent the Charter (Founding) Member organisations. The Board will oversee an Executive Committee comprising of 3 elected officers and 2 nominees appointed by the Board. The Board will create other action committees with specified mandate to address AAIH priorities.

Dues paid by members of the organization are deductible as a business expense. If any lobbying occurs, the portion that pays for lobbying about legislation is not tax deductible.

Yes, the organization will have the potential to raise revenue from sponsorships and industry events, especially if AAIH organizes a flagship AI conference independently or in partnership with one of the existing conferences. There is also the potential to raise revenue through publications and an accreditation service for certain AI activities in healthcare.

Any company or organization developing or investing in AI platforms for healthcare and willing to sign a member code of conduct committing to specific industry expectations. There will be no individual memberships initially.

As an industry convener, the AAIH will lead discussion on standardization and guidance. We embrace a multi-stakeholder approach; companies and institutions in particular healthcare applications are asked to participate in setting industry standards and crafting our guidelines which will inform ongoing conversations with regulatory bodies. Our view is that members committed to developing a sustainable and ethical industry will see participation in these drafted standards and guidelines as mutually beneficial, and will support universal compliance.

Not to our knowledge. The AAIH is an inclusive organization, and incipient or complementary efforts are welcomed to join our initiatives in order to foster continued growth and excellence in the industry.

We encourage and anticipate the participation of numerous large pharmaceutical, biotech, diagnostics, and medical devices firms investing in or utilizing AI in their operations.

We anticipate strong participation from the full gamut of tech firms participating in healthcare: hardware, software, integrators, infrastructure providers etc. We anticipate most tech firms will eventually invest in AI in healthcare to some extent and as such will take an interest in our industry stakeholder organization and advocacy efforts.

AAIH will begin as a global organization with headquarters in Washington D.C. USA, but with plans to have offices and affiliations in Europe, Asia/APAC, Australia, and other regions globally. We view this as an international industry with a global market, and intend to operate in all pertinent regions.

ai in healthcare
Benefits to AAIH Members and Society
  • Advocacy: Representation to healthcare and policy makers influencing the markets in which Healthcare AI will operate.
    • Community/ Networking: While this community by its very nature will be virtual and distributed, AAIH will offer an opportunity for leaders in the community to convene and discuss issues, challenges, and opportunities within the sector. We will create both a virtual and event-based networking service to facilitate business interactions, collaborations, and partnerships.
      • For Technology Developers: Engagement with AAIH offers a unique opportunity to engage with key stakeholders in other verticals, as well as potential client bases such as large pharma or patient populations
      • For Users/Integrators: Participation in AAIH offers consumers and data analysts the chance to engage with developers, to have their voices heard, and requirements delivered at the executive level.
      • For Investors: Participation in AAIH offers a view into key developments in the industry, and an opportunity to engage with the entrepreneurs making AI in Healthcare a reality
    • Access to information: We expect AAIH to become a repository for information, data, and metrics to track sector performance and provide other relevant information to support successful commercial adoption of these technologies.
    • Access to experts for AI enabled/enhanced Biomedical discovery and care delivery: AAIH will provide a forum for members to effectively tap into AI Subject Matter Experts for input, and to view associated platforms for acceleration of internal R&D programs to increase the probability of success.
    • Accreditation and Standardization: AAIH will lead the effort to develop relevant standards to support broader use and adoption of AI in healthcare. In addition, AAIH will begin development of an accreditation process to certify companies/organizations claiming to provide AI services in healthcare.
    • Communications/PR: AAIH will be a voice for the sector and will manage interactions with the media, public, and other key stakeholder groups.
    • Education: Educational outreach will begin as an activity of AAIH, and as demand increases may shift towards an education focused foundation for AI in Healthcare.

Dues will fund advocacy, operations and contract personnel to perform these functions. Dues will also be used to support special projects and initiatives prioritized by the Board.

We believe it should as establishing bona fides of AI Healthcare products will grow to be a key hurdle in universal acceptance, but this will be a decision taken up by the board after the launch of the organization. We would recommend creating a Board Task Force to review this in more detail and then asking the Task Force to analyze legal and tax issues and make a recommendation to the Board addressing benefits, risks, cost, potential revenues, etc.

Healthcare AI
Operations
  • AAIH was incorporated on August 31st, 2018
  • Formal launch is slated for January 7th, 2019
  • Inaugural BoD meeting will be on January 9th, 2019

Team Adjuvant: Adjuvant Partners (operational activities) and Holland Knight (coordinating the legal and advocacy).